Compare Allegion PLC (ALLE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs ResMed Inc. — how do they compare? Allegion PLC trades at $165.82 (market cap $14.32B), while ResMed Inc. trades at $225.19 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 2.3× Allegion PLC's market cap, and Allegion PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| ALLE | RMD | |
|---|---|---|
Market Cap | $14.32B | $32.61B |
Sector | Industrials | Health |
52-Week High | $179.77 | $293.73 |
52-Week Low | $125.65 | $182.82 |
Enterprise Value | $16.03B | $31.97B |
Dividend Yield | 1.26% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $166.18, up 0.39% on the day, showing strong momentum following better-than-expected Q2 2026 earnings. The stock demonstrates robust fundamentals with 15.36% net income margin and 33.73% ROE, though recent quarters show mixed earnings performance. Technical indicators suggest bullish momentum with the current price near resistance levels. Recent institutional buying and positive analyst coverage highlight growing confidence in the security products provider's growth trajectory.
Outlook remains positive with raised 2026 guidance and strong Americas segment performance driving optimism. Investment opportunity lies in continued margin expansion and market share gains, while risks include international segment weakness and rising input costs. The stock trades above consensus price target but offers potential upside to high target of $170.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
